Inclusion Criteria:  Age ≥18 years, regardless of gender; The result of the RT-PCR test by fluorescence of respiratory or blood samples must be positive for COVID-19, or the viral gene sequencing of respiratory tract samples must be highly homologous with COVID-19; Individuals with COVID-19 must meet the diagnostic criteria of the "latest version of the clinical guidelines for COVID-19" issued by the World Health Organization (WHO) on June 4th, 2020; Symptomatic patients who meet the WHO case definition for COVID-19 with no evidence of bacterial pneumonia or hypoxia (Sat O2 <95%). Voluntary participation and signing of the Informed Consent Form.  Exclusion Criteria:  Be aware or suspected of being allergic to any of the components of AZVUDINE tablets (inactive ingredients: microcrystalline cellulose, hydrated lactose, polyvinylpyrrolidone K30, croscarmellose sodium, magnesium stearate); Individual with shortness of breath and Sat O2 < 95%; or any other symptom that requires treatment through hospitalization; Patients with liver disease (total bilirubin ≥2mg/dL, ALT/TGP, and AST/TGO ≥5 times the normal limit); Patients with a history of known liver disease (Chirrhosis, with ChildPugh classification B and C); Patients with a history of renal failure (Glomerular Filtration Rate </=60mL/min/1.73m²); Patients with a history of congestive heart failure (grade 3/4 NYHA), untreated symptomatic arrhythmias, or myocardial infarction for 6 months; Individuals with malabsorption syndrome, or other conditions that affect gastrointestinal absorption, and circumstances in which patients require intravenous nutrition, or cannot take medications by mouth or nasogastric; Total neutrophil count <750 cells/L; Women who are pregnant or lactating, or of childbearing potential during the study period and within 6 months after termination of administration; Individuals who have participated in another clinical trial and used an experimental drug in the past 12 weeks; Patient actively being treated for HIV, Hepatitis C, or Hepatitis B; Patients being treated with other antivirals (e.g., lopinavir/ritonavir, remdesivir, umifenovir/arbidol, favipiravir, interferon-α) or immunosuppressive drugs for other medical conditions; Patients being treated with monoclonal antibodies (e.g., tocilizumab and sarilumab/kevzara); Any clinically significant medical condition or medical history that, in the investigator's opinion, may discourage study participation, such as corrected QT interval >480 on the electrocardiogram, among other conditions.